Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook

Heron Therapeutics

10/08/2026 13:08

Overview
US biotechnology firm's Q2 net revenue rose 1.3% yr/yr to $37.7 mln
Company withdrew full-year 2026 guidance citing CINVANTI patent uncertainty and strategic review
Heron amended credit facility, reducing principal by up to $17.5 mln and resetting covenants

Outlook
Heron withdrew full-year 2026 guidance for net product sales and Adjusted EBITDA
Company cites uncertainty over generic entry for CINVANTI and paused sales force expansion
Heron is considering strategic alternatives but has not set a timetable for this process

Result Drivers
ACUTE CARE GROWTH - Co said net revenue from acute care products, including ZYNRELEF and APONVIE, rose sharply yr/yr
ONCOLOGY REVENUE DECLINE - Co said oncology supportive care revenue fell, mainly due to lower sales of CINVANTI and SUSTOL
CINVANTI PATENT UNCERTAINTY - Co cited court decision on CINVANTI patents as reason for guidance withdrawal and sales force expansion pause

Company press release: ID:nGNX9ZTxs7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Product Sales
 
$37.67 mln
 
Q2 Loss Per Share
 
$0.03
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Heron Therapeutics Inc is $2.50, about 409.4% above its August 7 closing price of $0.49

Reuters Recommended Reads
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY  growth
Aug 7 - bioAffinity Technologies Q2 revenue rises on CyPath Lung demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)